Dyadic International (DYAI) Stock Price, Quote & News

Company Profile

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large...

Industry: Biotechnology

Sector: Healthcare

Phone: 561 743 8333

Fax: 561 743 8343

Website: www.dyadic.com

Address:

1044 North U.S. Highway One, Suite 201, Jupiter, United States

Arb_raccoon Jun. 18 at 9:53 PM

$DYAI “I got in at 0.72” @Jirish72

0 · Reply

Glopolon Jun. 18 at 9:42 PM

$DYAI They will have 360 days to regain compliance.

0 · Reply

Arb_raccoon Jun. 18 at 9:10 PM

$DYAI don’t bet against the raccoon

1 · Reply

focafoca99 Jun. 18 at 2:08 PM

$DYAI receives a Nasdaq delisting notice for failing to meet the $1 bid price rule and plans to request a hearing.

1 · Reply

WallStreetSignals Jun. 18 at 12:15 PM

$DYAI #News Dyadic International, Inc. (Nasdaq: #DYAI) is gaining interest in its C1 protein production platform as global efforts to tackle the Bundibugyo Ebola virus (BDBV) intensify. https://www.globenewswire.com/news-release/2026/06/15/3311689/0/en/dyadic-highlights-accelerated-interest-in-c1-biomanufacturing-platform-amid-ebola-preparedness-activities-and-growing-commercial-adoption.html #TheBullRunShow #Ebola #Dyadic #Biotech #Healthcare #Innovation

0 · Reply

Arb_raccoon Jun. 17 at 10:39 PM

$DYAI you guys do realize Ebola is the worst commercial opportunity of any disease right?

3 · Reply

Knucklehead_ Jun. 17 at 9:29 PM

$DYAI @bundy3333 https://www.nasdaq.com/articles/dyadic-international-dyai-price-target-increased-4000-714

0 · Reply

MikeTechnician Jun. 17 at 7:48 PM

$DYAI

0 · Reply

Knucklehead_ Jun. 17 at 4:06 PM

$DYAI Based on the most recent analyst data, centers around $7–$9 per share, representing ~700%–900% upside from current levels. This is not my opinion — it is directly grounded in analyst forecasts. Cheers 🥂

1 · Reply

MikeTechnician Jun. 17 at 4:06 PM

$DYAI - highlighted increasing interest in its proprietary C1 protein production platform as global infectious disease preparedness efforts intensify in response to the ongoing Bundibugyo Ebola virus (BDBV) outbreak and as the Company continues to advance commercial adoption across multiple high-growth markets.

0 · Reply

Dyadic International Transcript: AGM 2026

Jun 18, 2026, 8:00 AM EDT - 2 days ago

Dyadic International Proxy statement: Proxy filing

Jun 15, 2026, 7:25 AM EDT - 5 days ago

Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

May 28, 2026, 10:30 AM EDT - 23 days ago

Dyadic International Transcript: Lytham Partners Spring 2026 Investor Conference

2026-05-28T13:47:19.000Z - 23 days ago

Dyadic International, Scripps Research team to evaluate Hantavirus vaccine

May 28, 2026, 7:25 AM EDT - 23 days ago

Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

May 21, 2026, 4:05 PM EDT - 4 weeks ago

Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

May 21, 2026, 3:45 PM EDT - 4 weeks ago

Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ET

May 20, 2026, 10:00 AM EDT - 4 weeks ago

Dyadic International Transcript: Sidoti Micro-Cap Virtual Conference

May 19, 2026, 9:35 AM EDT - 4 weeks ago

Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference

May 19, 2026, 7:00 AM EDT - 4 weeks ago

Dyadic International Slides: Investor presentation

May 13, 2026, 5:00 PM EDT - 5 weeks ago

Dyadic International Earnings Call Transcript: Q1 2026

May 13, 2026, 5:00 PM EDT - 5 weeks ago

Dyadic International Earnings release: Q1 2026

May 13, 2026, 5:00 PM EDT - 5 weeks ago

Dyadic International Quarterly report: Q1 2026

May 13, 2026, 4:05 PM EDT - 5 weeks ago

Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress

May 12, 2026, 8:00 AM EDT - 5 weeks ago

Dyadic International Proxy statement: Proxy filing

May 1, 2026, 5:11 PM EDT - 7 weeks ago

Dyadic International Slides

May 1, 2026, 8:00 AM EDT - 7 weeks ago

Dyadic International Proxy statement: Proxy filing

Apr 29, 2026, 4:05 PM EDT - 7 weeks ago

Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026

Mar 25, 2026, 5:00 PM EDT - 3 months ago

Dyadic International Earnings Call Transcript: Q4 2025

Mar 25, 2026, 5:00 PM EDT - 3 months ago

Dyadic International Earnings release: Q4 2025

Mar 25, 2026, 5:00 PM EDT - 3 months ago

Dyadic International Annual report: Q4 2025

Mar 25, 2026, 4:51 PM EDT - 3 months ago

Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

2026-03-16T11:36:49.000Z - 3 months ago

Dyadic International enter distribution partnership with IBT Bioservices

Mar 16, 2026, 7:20 AM EDT - 3 months ago

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

Mar 12, 2026, 1:30 PM EDT - 3 months ago

Dyadic International Transcript: Life Sciences Virtual Investor Forum

Mar 11, 2026, 4:10 PM EDT - 3 months ago

Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

2026-03-04T12:23:22.000Z - 3 months ago

Dyadic International, Fermbox Bio launch of RNase-Free

Mar 4, 2026, 7:20 AM EST - 3 months ago

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

2026-03-02T12:33:34.000Z - 3 months ago

Dyadic International, Inzymes announce planned 2026 commercialization

2026-03-02T12:29:56.000Z - 3 months ago

Dyadic International, Inzymes announce planned 2026 commercialization

Mar 2, 2026, 7:20 AM EST - 3 months ago

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

Feb 17, 2026, 7:25 AM EST - 4 months ago

Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin

2025-12-17T12:26:09.000Z - 6 months ago

Dyadic International, Fermbox Bio expand strategic collaboration

2025-12-15T12:25:44.000Z - 6 months ago

Dyadic International establishes commercial partnership with Opes

Dec 15, 2025, 7:20 AM EST - 6 months ago

Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic's Recombinant Growth Factors and Media Proteins

Dec 9, 2025, 9:30 AM EST - 6 months ago

Dyadic International Transcript: IAccess Alpha Virtual MicroCap Conference

Dec 1, 2025, 7:25 AM EST - 7 months ago

Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets

2025-11-12T22:30:23.000Z - 7 months ago

Dyadic International reports Q3 EPS (6c), consensus (4c)

Nov 12, 2025, 5:00 PM EST - 7 months ago

Dyadic International Earnings Call Transcript: Q3 2025

Nov 12, 2025, 5:00 PM EST - 7 months ago

Dyadic International Earnings release: Q3 2025

Nov 12, 2025, 5:00 PM EST - 7 months ago

Dyadic International Quarterly report: Q3 2025

Nov 12, 2025, 4:05 PM EST - 7 months ago

Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress

2025-11-10T12:38:06.000Z - 7 months ago

Dyadic International, ERS Genomics announces CRISPR/Cas9 license

Oct 29, 2025, 7:25 AM EDT - 8 months ago

Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025

2025-10-23T10:10:55.000Z - 8 months ago

Dyadic International assumed with a Buy at H.C. Wainwright

2025-10-06T12:50:17.000Z - 9 months ago

Dyadic International announces achievement of milestone payments

Oct 6, 2025, 8:30 AM EDT - 9 months ago

Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments

Sep 18, 2025, 9:15 AM EDT - 9 months ago

Dyadic International Transcript: Small-Cap Virtual Conference

2025-09-08T13:20:27.000Z - 10 months ago

Craig-Hallum bullish on Dyadic International, initiates with a Buy

2025-09-08T11:20:43.000Z - 10 months ago

Dyadic International initiated with a Buy at Craig-Hallum

Sep 4, 2025, 9:00 AM EDT - 10 months ago

Dyadic to Present at Investor Conferences and BPI East

Aug 13, 2025, 5:00 PM EDT - 11 months ago

Dyadic International Earnings Call Transcript: Q2 2025

Aug 13, 2025, 5:00 PM EDT - 11 months ago

Dyadic International Quarterly report: Q2 2025

Aug 13, 2025, 5:00 PM EDT - 11 months ago

Dyadic International Earnings release: Q2 2025

Aug 13, 2025, 4:01 PM EDT - 11 months ago

Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

Aug 13, 2025, 4:00 PM EDT - 11 months ago

Dyadic International Slides: Investor Presentation

Aug 5, 2025, 4:11 PM EDT - 11 months ago

Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

2025-07-31T12:50:32.000Z - 11 months ago

Dyadic International prices 6.05M shares at 95c in underwritten public offering

Jul 31, 2025, 8:47 AM EDT - 11 months ago

UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

2025-07-31T11:41:14.000Z - 11 months ago

Dyadic International prices 6.05M shares in underwritten public offering

Jul 31, 2025, 7:30 AM EDT - 11 months ago

Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

2025-07-30T20:13:50.000Z - 11 months ago

Dyadic International announces common stock offering, no amount given

Jul 30, 2025, 4:02 PM EDT - 11 months ago

Dyadic International, Inc. Announces Proposed Public Offering of Common Stock

2025-07-02T20:05:15.000Z - 1 year ago

Dyadic International rebrands as Dyadic Applied BioSolutions

Jul 2, 2025, 4:00 PM EDT - 1 year ago

Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions

2025-06-02T12:45:52.000Z - 1 year ago

Dyadic International names Joe Hazelton as President

Jun 2, 2025, 8:35 AM EDT - 1 year ago

Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

May 14, 2025, 5:00 PM EDT - 1 year ago

Dyadic International Earnings Call Transcript: Q1 2025

May 14, 2025, 5:00 PM EDT - 1 year ago

Dyadic International Quarterly report: Q1 2025

May 14, 2025, 5:00 PM EDT - 1 year ago

Dyadic International Earnings release: Q1 2025

May 1, 2025, 3:00 PM EDT - 1 year ago

Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Dyadic International Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Dyadic International Proxy statement: Proxy Filing

Apr 16, 2025, 2:00 PM EDT - 1 year ago

Dyadic to Present at World Vaccine Congress | Washington

Mar 26, 2025, 5:00 PM EDT - 1 year ago

Dyadic International Earnings Call Transcript: Q4 2024

Mar 26, 2025, 5:00 PM EDT - 1 year ago

Dyadic International Annual report: Q4 2024

Mar 26, 2025, 5:00 PM EDT - 1 year ago

Dyadic International Earnings release: Q4 2024

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Dyadic Reports 2024 Year-End Financial Results and Business Updates

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Dyadic International Registration statement: Registration Filing

Mar 12, 2025, 4:00 PM EDT - 1 year ago

Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025

Mar 6, 2025, 8:30 AM EST - 1 year ago

Dyadic to Attend Multiple Industry Events in March

Jan 6, 2025, 8:30 AM EST - 1 year ago

Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Nov 21, 2024, 8:30 AM EST - 1 year ago

Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology

Nov 12, 2024, 5:00 PM EST - 1 year ago

Dyadic International Earnings Call Transcript: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Dyadic International Earnings release: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Dyadic International Quarterly report: Q3 2024

Nov 4, 2024, 4:30 PM EST - 1 year ago

Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Dyadic Expands Global Presence with Participation in Key Industry Events

Sep 23, 2024, 9:50 AM EDT - 1 year ago

Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference

Aug 13, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Earnings Call Transcript: Q2 2024

Aug 13, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Quarterly report: Q2 2024

Aug 13, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Earnings release: Q2 2024

Jul 30, 2024, 4:00 PM EDT - 2 years ago

Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

Jun 28, 2024, 8:30 AM EDT - 2 years ago

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

May 30, 2024, 4:30 PM EDT - 2 years ago

Dyadic to Attend Industry Events in June

May 14, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Earnings Call Transcript: Q1 2024

May 14, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Quarterly report: Q1 2024

May 14, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Earnings release: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 8, 2024, 8:30 AM EDT - 2 years ago

Dyadic to Attend Industry and Investor Events in May

Apr 30, 2024, 4:30 PM EDT - 2 years ago

Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Dyadic International Registration statement: Registration Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Dyadic International Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Dyadic International Proxy statement: Proxy Filing

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Earnings Call Transcript: Q4 2023

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Annual report: Q4 2023

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Dyadic International Earnings release: Q4 2023

Mar 28, 2024, 4:00 PM EDT - 2 years ago

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Mar 28, 2024, 8:30 AM EDT - 2 years ago

Dyadic Announces Change in Board and Management Leadership Roles

Mar 27, 2024, 8:30 AM EDT - 2 years ago

Dyadic to Attend Industry Events in April

Mar 26, 2024, 8:30 AM EDT - 2 years ago

Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

Mar 21, 2024, 8:30 AM EDT - 2 years ago

Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California

Mar 14, 2024, 4:30 PM EDT - 2 years ago

Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024

Mar 11, 2024, 9:57 AM EDT - 2 years ago

CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

Mar 11, 2024, 8:30 AM EDT - 2 years ago

Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

Arb_raccoon Jun. 18 at 9:53 PM

$DYAI “I got in at 0.72” @Jirish72

0 · Reply

Glopolon Jun. 18 at 9:42 PM

$DYAI They will have 360 days to regain compliance.

0 · Reply

Arb_raccoon Jun. 18 at 9:10 PM

$DYAI don’t bet against the raccoon

1 · Reply

focafoca99 Jun. 18 at 2:08 PM

$DYAI receives a Nasdaq delisting notice for failing to meet the $1 bid price rule and plans to request a hearing.

1 · Reply

WallStreetSignals Jun. 18 at 12:15 PM

0 · Reply

Arb_raccoon Jun. 17 at 10:39 PM

$DYAI you guys do realize Ebola is the worst commercial opportunity of any disease right?

3 · Reply

Knucklehead_ Jun. 17 at 9:29 PM

$DYAI @bundy3333 https://www.nasdaq.com/articles/dyadic-international-dyai-price-target-increased-4000-714

0 · Reply

MikeTechnician Jun. 17 at 7:48 PM

$DYAI

0 · Reply

Knucklehead_ Jun. 17 at 4:06 PM

1 · Reply

MikeTechnician Jun. 17 at 4:06 PM

0 · Reply

MartyCortez Jun. 17 at 3:22 PM

$DYAI Ebola in the Congo

0 · Reply

bundy3333 Jun. 16 at 4:26 PM

$DYAI Surely as they have missed it since June, 4th 2026 and are supposed loosing listing before the opening ... ... See you at OTC in December DYAIQ

1 · Reply

topstockalerts Jun. 15 at 8:39 PM

$DYAI the chart is starting to tell a story

0 · Reply

Arb_raccoon Jun. 15 at 7:54 PM

$DYAI Awful expression platform with no real glycosilation solution

1 · Reply

Arb_raccoon Jun. 15 at 7:54 PM

$DYAI Dont be fooled - the guys pumping this stock are down 80%

0 · Reply

Glopolon Jun. 15 at 2:54 PM

$DYAI They have something the world needs, though. Much better than mRNA..

0 · Reply

Glopolon Jun. 15 at 2:54 PM

$DYAI Shorts want to pound this down until December 2026. Just FYI.

0 · Reply

bundy3333 Jun. 15 at 2:26 PM

$DYAI Any Real and Actual News - and no repetitions on the assumed regular basis - today or since June, 5th? E.g. regarding the SEC filing because of NASDAQ letter, Dec-19-2025? Failing the 10 days period by June, 4th 2026. ?

1 · Reply

WallStreetSignals Jun. 15 at 1:31 PM

$DYAI is reporting accelerated interest in its proprietary C1 Biomanufacturing Platform, driven by ongoing Ebola preparedness initiatives and increasing commercial adoption across the biotechnology sector. The C1 platform continues to gain recognition for its ability to deliver rapid, scalable, and cost-effective production of proteins, vaccines, and therapeutic candidates—helping address global health challenges and emerging infectious disease threats. https://dyadic.com/dyadic-highlights-accelerated-interest-in-c1-biomanufacturing-platform-amid-ebola-preparedness-activities-and-growing-commercial-adoption/ #DYAI #Dyadic #NASDAQ #Biotechnology #Biomanufacturing #C1Platform #EbolaPreparedness #VaccineDevelopment #HealthcareInnovation #LifeSciences #BreakingNews #InvestSmart #StockMarket #BullMarket #TheBullRunShow 🚀📈🧬

0 · Reply

Mcguiresjackson Jun. 15 at 12:40 PM

$DYAI starting here.lfg

0 · Reply

MikeTechnician Jun. 15 at 12:23 PM

$DYAI News Out - Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption https://finance.yahoo.com/sectors/healthcare/articles/dyadic-highlights-accelerated-interest-c1-112500620.html

0 · Reply

ECST Jun. 15 at 11:51 AM

$DYAI

0 · Reply

Market Cap	28.50M
Revenue (ttm)	3.09M
Net Income (ttm)	-7.36M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	6.53
Profit Margin	-238.19%
Debt to Equity Ratio	0.00

Volume	217,400
Avg Vol	289,978
Day's Range	N/A - N/A
Shares Out	36.44M
Stochastic %K	54%
Beta	1.17
Analysts	Strong Sell
Price Target	$6.00